Patents by Inventor Rune Salbo

Rune Salbo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 11858992
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: January 2, 2024
    Assignee: NOVO NORDISK A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • METHODS OF TREATING AUTOIMMUNE DISEASE OR CHRONIC INFLAMMATION WITH ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20210253697
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 19, 2021
    Inventors: Vibeke Westphal STENNICKE, Christine Brender READ, Susanne Nedergaard GRELL, Charlotte WIBERG, Rune SALBO, Anette HENRIKSEN, Soeren PADKJAER
  • Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 10906975
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: February 2, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20190194321
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: December 4, 2018
    Publication date: June 27, 2019
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal STENNICKE, Christine Brender READ, Susanne Nedergaard GRELL, Charlotte WIBERG, Rune SALBO, Anette HENRIKSEN, Soeren PADKJAER
  • Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 10189904
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: January 29, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF
    Publication number: 20170320946
    Abstract: Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-?. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 9, 2017
    Inventors: Marco Colonna, Axel Bouchon, Rune Salbo, Charlotte Wiberg, Vibeke Westphal Stennicke, Anette Henriksen, Mette Dahl Andersen
  • Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 9550830
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: January 24, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Novel Methods and Antibodies for Treating Coagulapathy
    Publication number: 20160297892
    Abstract: The present invention relates to pro-coagulant human Protein S inhibitors, such as antibodies or antigen-binding fragments thereof that can be administered subcutaneously as prophylactic treatment for haemophilia patients regardless of inhibitor status and without interfering with non-coagulant functions of Protein S.
    Type: Application
    Filed: November 7, 2014
    Publication date: October 13, 2016
    Inventors: Helle Heibroch Petersen, Mette Brunsgaard Hermit, Heidi Lindgreen Holmberg, Berit Olsen Krogh, Kristian Kjaergaard, Mette Dahl Andersen, Rune Salbo, Emily Waters, Lisbeth Moreau Andersen, Kristoffer Winther Balling
  • NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF
    Publication number: 20160251434
    Abstract: Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-?. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
    Type: Application
    Filed: February 6, 2015
    Publication date: September 1, 2016
    Inventors: Marco Colonna, Axel Bouchon, Rune Salbo, Charlotte Wiberg, Vibeke Westphal Stennicke, Anette Henriksen, Mette Dahl Andersen
  • Antibodies that Bind and Block Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1)
    Publication number: 20150274825
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: February 26, 2015
    Publication date: October 1, 2015
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 9000127
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 7, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
    Patent number: 8981061
    Abstract: Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-?. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: March 17, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Marco Colonna, Axel Bouchon, Rune Salbo, Charlotte Wiberg, Vibeke W. Stennicke, Anette Henriksen, Mette D. Andersen
  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20130309239
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: July 30, 2013
    Publication date: November 21, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer